Cargando…

Association between disease-modifying therapies for multiple sclerosis and healthcare utilisation on a population level: a retrospective cohort study

OBJECTIVE: Disease-modifying therapy (DMT) use in multiple sclerosis (MS) has increased significantly. However, the impact of DMTs on healthcare use is limited and conflicting, and rarely examined at a population level. This study examined the association between DMTs and healthcare utilisation at t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Al-Sakran, Lina, Marrie, Ruth Ann, Blackburn, David, Knox, Katherine, Evans, Charity
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2019
Materias:	Neurology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6887031/ https://www.ncbi.nlm.nih.gov/pubmed/31772108 http://dx.doi.org/10.1136/bmjopen-2019-033599

Ejemplares similares

Effect of adherence to the first-generation injectable immunomodulatory drugs on disability accumulation in multiple sclerosis: a longitudinal cohort study
por: Zhang, Tingting, et al.
Publicado: (2017)

Sex and age differences in the Multiple Sclerosis prodrome
por: Yusuf, Fardowsa L. A., et al.
Publicado: (2022)

Persistence to disease-modifying therapies for multiple sclerosis in a Canadian cohort
por: Melesse, Dessalegn Y, et al.
Publicado: (2017)

Attitudes of people with multiple sclerosis toward brain donation
por: Marrie, Ruth Ann, et al.
Publicado: (2023)

Development and Internal Validation of a Disability Algorithm for Multiple Sclerosis in Administrative Data
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Comparing the MSIS-29 and the Health Utilities Index Mark III in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Good multiple sclerosis (MS) care and how to get there in Canada: Perspectives of Canadian healthcare providers working with persons with MS
por: Petrin, Julie, et al.
Publicado: (2023)

Medication adherence in multiple sclerosis as a potential model for other chronic diseases: a population-based cohort study
por: Evans, Charity, et al.
Publicado: (2021)

Disease-Modifying Drugs for Multiple Sclerosis and Association With Survival
por: Ng, Huah Shin, et al.
Publicado: (2022)

The Canadian survey of health, lifestyle and ageing with multiple sclerosis: methodology and initial results
por: Ploughman, Michelle, et al.
Publicado: (2014)

Application of pharmacogenomics to investigate adverse drug reactions to the disease-modifying treatments for multiple sclerosis: a case–control study protocol for dimethyl fumarate-induced lymphopenia
por: Kowalec, Kaarina, et al.
Publicado: (2017)

Women's Health in Multiple Sclerosis: A Scoping Review
por: Ross, Lindsay, et al.
Publicado: (2022)

Models of Care in Multiple Sclerosis: A Survey of Canadian Health Providers
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Use of Benzodiazepines and Z-Drugs in Multiple Sclerosis
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Disease-modifying drugs for multiple sclerosis and subsequent health service use
por: Ng, Huah Shin, et al.
Publicado: (2021)

Multiple sclerosis disease-modifying drug use by immigrants: a real-world study
por: Graf, Jonas, et al.
Publicado: (2023)

Determinants of non-adherence to disease-modifying therapies in multiple sclerosis: A cross-Canada prospective study
por: McKay, Kyla A, et al.
Publicado: (2016)

Switching to second line MS disease-modifying therapies is associated with decreased relapse rate
por: Marriott, James John, et al.
Publicado: (2023)

Performance of Regression-Based Norms for Cognitive Functioning of Persons With Multiple Sclerosis in an Independent Sample
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Editorial: Disease modifying therapies in multiple sclerosis
por: Bonavita, Simona, et al.
Publicado: (2022)

Effects of Vascular Comorbidity on Cognition in Multiple Sclerosis Are Partially Mediated by Changes in Brain Structure
por: Marrie, Ruth Ann, et al.
Publicado: (2022)

Differences in resting state functional connectivity relative to multiple sclerosis and impaired information processing speed
por: Carter, Sean L., et al.
Publicado: (2023)

Pregnancy-related healthcare utilization among women with multiple sclerosis
por: Mainguy, Marie, et al.
Publicado: (2023)

Influence of Pregnancy in Multiple Sclerosis and Impact of Disease-Modifying Therapies
por: Simone, Isabella Laura, et al.
Publicado: (2021)

Editorial: Preventing multiple sclerosis
por: Dobson, Ruth, et al.
Publicado: (2022)

Disease Activity and Progression of Disability in Multiple Sclerosis Patients Aged Over 50 With or Without Disease-Modifying Drug Treatment: A Retrospective Cohort Study
por: Kondo, Akihiro, et al.
Publicado: (2023)

Multiple sclerosis and exercise—A disease-modifying intervention of mice or men?
por: Martin, Sarah-Jane, et al.
Publicado: (2023)

The multiple sclerosis relapse experience: patient-reported outcomes from the North American Research Committee on Multiple Sclerosis (NARCOMS) Registry
por: Nickerson, Molly, et al.
Publicado: (2013)

Predicting Multiple Sclerosis: Challenges and Opportunities
por: Hone, Luke, et al.
Publicado: (2022)

Disease-Modifying Drugs and Breastfeeding in Multiple Sclerosis: A Narrative Literature Review
por: Capone, Fioravante, et al.
Publicado: (2022)

Societal economic burden of multiple sclerosis and cost-effectiveness of disease-modifying therapies
por: Simoens, Steven
Publicado: (2022)

The Barancik lecture: Comorbidity in multiple sclerosis—Looking backward, looking forward
por: Marrie, Ruth Ann
Publicado: (2023)

The Association Between Persistence and Adherence to Disease-Modifying Therapies and Healthcare Resource Utilization and Costs in Patients With Multiple Sclerosis
por: Pardo, Gabriel, et al.
Publicado: (2022)

Pregnancy Outcomes in Patients With Multiple Sclerosis Exposed to Natalizumab—A Retrospective Analysis From the Austrian Multiple Sclerosis Treatment Registry
por: Guger, Michael, et al.
Publicado: (2020)

Retrospective cohort study of the relationship between systolic blood pressure variability and multiple sclerosis disability
por: Goldman, Myla D, et al.
Publicado: (2020)

Serotonergic drug repurposing in multiple sclerosis: A new possibility for disease-modifying therapy
por: Melnikov, Mikhail, et al.
Publicado: (2022)

Impact of histone modifier-induced protection against autoimmune encephalomyelitis on multiple sclerosis treatment
por: Jayaraman, Sundararajan, et al.
Publicado: (2022)

Demographic and Clinical Predictors of Disease Severity in Patients With Multiple Sclerosis: A Retrospective Cross-Sectional Analysis
por: Almuklass, Awad M, et al.
Publicado: (2023)

Administrative data for observational research in multiple sclerosis: Opportunities and challenges
por: Marrie, Ruth Ann, et al.
Publicado: (2021)

Comorbidity in Multiple Sclerosis
por: Magyari, Melinda, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ole1n716g0v4sf8ufh8eba2evh